Correlation Between Halozyme Therapeutics and Viking Therapeutics
Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Viking Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Viking Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Halozyme Therapeutics and Viking Therapeutics, you can compare the effects of market volatilities on Halozyme Therapeutics and Viking Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Viking Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Viking Therapeutics.
Diversification Opportunities for Halozyme Therapeutics and Viking Therapeutics
0.17 | Correlation Coefficient |
Average diversification
The 3 months correlation between Halozyme and Viking is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Viking Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viking Therapeutics and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Viking Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viking Therapeutics has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Viking Therapeutics go up and down completely randomly.
Pair Corralation between Halozyme Therapeutics and Viking Therapeutics
Given the investment horizon of 90 days Halozyme Therapeutics is expected to generate 1.23 times more return on investment than Viking Therapeutics. However, Halozyme Therapeutics is 1.23 times more volatile than Viking Therapeutics. It trades about -0.02 of its potential returns per unit of risk. Viking Therapeutics is currently generating about -0.35 per unit of risk. If you would invest 5,046 in Halozyme Therapeutics on August 28, 2024 and sell it today you would lose (267.00) from holding Halozyme Therapeutics or give up 5.29% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Halozyme Therapeutics vs. Viking Therapeutics
Performance |
| Timeline |
| Halozyme Therapeutics |
| Viking Therapeutics |
Halozyme Therapeutics and Viking Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Halozyme Therapeutics and Viking Therapeutics
The main advantage of trading using opposite Halozyme Therapeutics and Viking Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Viking Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viking Therapeutics will offset losses from the drop in Viking Therapeutics' long position.| Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
| Viking Therapeutics vs. Terns Pharmaceuticals | Viking Therapeutics vs. Akero Therapeutics | Viking Therapeutics vs. Madrigal Pharmaceuticals | Viking Therapeutics vs. Sarepta Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Complementary Tools
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |